GlobalLink Applanga Solution Reduces eCOA Study Start-up Times and Increases Global Patient Access to Clinical Trials
TransPerfect, the world’s largest provider of language and technology solutions for global business, announced that its GlobalLink Applanga technology has been selected by Clario to streamline translation processes.
AI and ML News: AI and Machine Learning Training for AWS Sustainable Cities Accelerator
“Clario has integrated Applanga in a way that has enabled them to improve quality and efficiency. We are pleased that our technology has helped them reduce risk, cut costs, and succeed in their mission to get treatments to market safely and quickly.”
Clario is a healthcare technology company that delivers the leading endpoint technology solutions for decentralized (DCT), hybrid, and site-based clinical trials. Clario’s Translation Workbench is used to streamline the localization process, including managing multilingual content for licensed scales and data collecting material, as well as ensuring on-screen accuracy. Managing around 150 studies at a time, with each study averaging 20 languages and eight assessments, Clario needed technology that offered them the automation to speed up the eCOA study kick-off process.
GlobalLink Applanga is a cloud-based translation management system with features developed specifically for web-based applications, including handheld devices and clinical apps, enabling Clario to more effectively address app localization requirements.
By connecting with Applanga via API, the Clario Translation Workbench initiates the localization process and streamlines screenshot review and approval. Screenshot capture is automated for each assessment, pulling text and pushing screenshots with minimal effort.
Browse The Complete News About Blockchain : Blockchain Partnership: PraSaga and Metahug Gamify Web3 Education Via Roblox
As a result of implementing Applanga, Clario experienced lessened turnaround times by 30%. These reductions were achieved by decreasing time spent in communication between TransPerfect and Clario, eliminating manual work necessary to generate accurate screenshots and translations on eCOA applications, and minimizing defects and human errors, which reduced the burden on quality assurance staff.
“Our clients need to deploy studies in multiple countries and ensure patients have access to accurate and timely translations of their electronic, clinical outcomes assessments. Without these, pharma and biopharma clients face delays in getting new medicines to patients, and patients could be unable to provide vital information about their health. With Clario’s global reach and TransPerfect’s technology, we can help increase patient access and speed up overall study set-up times,” said Terry Burke, EVP eCOA.
TransPerfect President and CEO Phil Shawe remarked, “Clario has integrated Applanga in a way that has enabled them to improve quality and efficiency. We are pleased that our technology has helped them reduce risk, cut costs, and succeed in their mission to get treatments to market safely and quickly.”
Next-gen AI-On-Demand Platform : European Commission Pumps in $9.15 Million to Develop Next-gen AI-On-Demand Platform
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.